-
CSR Summary Not Yet Available
-
NCT02951819
-
Primary Citation Trial has yet to be published
-
You are not logged in.
Please login to continue selecting trials.
Trial Information
Generic NameDaratumumabProduct NameDARZALEX®Therapeutic AreaCancers and Other NeoplasmsEnrollment101% Female36%% White81%
Product ClassMonoclonal AntibodySponsor Protocol Number54767414MMY2012Data PartnerJohnson & JohnsonCondition StudiedMultiple MyelomaMean/Median Age (Years)64
Supporting Documentation
- Collected Datasets Available
- Data Definition Specification Available
- Protocol with Amendments Available
- Statistical Analysis Plan Available
- Clinical Study Report Available